Chondroprotectors in theraphy of osteoarthritis
Keywords:
osteoarthritis, chondroprotectors, elderly patientsAbstract
Osteoarthritis (ОА) is a multifactorial disease associated with age, which is characterized by high polymorbidity, level of disability and death. In elderly patients with OA pain therapy especially related to factors such as a significant decrease in physical activity, the presence of comorbid disease (mainly heart disease) and complications caused by irrational drug therapy.
Available in an elderly patient OA various somatic diseases and a wide range of treatments used for their medicines suggest the choice of individual treatment strategy that takes into account the ratio of the alleged benefits and possible risks of the purpose of each drug funds in favor of the most safe and effective therapy.
References
Sellam, J. Osteoarthrosis: pathogenesis, clinical aspects and diagnosis [Text] / J. Sellam, G. Herrero-Beamont, F Berenbaum // Arthritis Rheum. – 2009. – Vol. 60(2) . –Р. 524-533.
Bekkers, J.E. Diagnostic modalities for diseased articular cartilage – from defect to degeneration: a review [Text] / J.E. Bekkers, L. Creemers, W.J. Dhert, D.B. Saris // Cartilage. – 2010. – Vol. 1. – Р. 157-164.
Alekseeva, L.I. Symptomatic slow-acting drugs in the treatment of OA [Text] / L.I. Alekseeva // Consilium medicus. – 2009. – № 11 (9). – Р. 100-104.
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. [Text] / C.G. Helmick, D.T. Felson, R.C. Lawrence [et al.] // Arthritis & Rheum. – 2008. – Vol. 58. – Р. 15-25.
The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study / M. Cross, E. Smith, D. Hoy [et al.] // Ann. Rheum. Dis. – 2014. – Vol. 73 (7).– P. 1316-1322.
Van der Wall, A.C. Cost analysis favours SPECT over PET and CTA for evaluation of coronary artery disease: the SPARC study [Text] / A.C. Van der Wall // Neth Heart J. – 2014. – Vol. 22. – Р. 257-258.
Clinical recommendations. Rheumatology [Text] / Ed. E.L. Nasonov // M.: GEOTAR–Media, 2008. – P. 99-111
Luger, E.O. The challenge: understanding the molecular pathogenesis of osteoarthritis and developing innovative therapeutic concepts [Text] / E.O. Luger, A. Radbruch // Z Rheumatol. – 2014. – Vol. 73 (4). – Р. 310- 314.
Subchondral bone sclerosis in osteoarthritis: not just an innocent bystander [Text] / D. Lajeunesse, F. Massicotte, J.P. Pelletier [et al.] // Modern Rheumatology. – 2003. – Vol. 13. – Р. 7–14.
Roemer, F.W. Imaging in OA: what have we learned and where are we going? [Text] / F.W. Roemer // Osteoarthr. Cartil. – 2010. – Vol. 18 (Suppl. 2). – 1-7.
Mok, T.M. Rheumatology News & Views from APLAR Region [Text] / T.M Mok. // Int. J. Rheum. Dis. – 2014. – Vol. 17. – Р. 486-487.
Chronic disability trends in elderly United States populations 1982–1994 [Text] / K.G. Manton [et al.] // Proceedings of the National Academy of Sciences. – 1997. – Vol. 94. – Р. 2593–2598.
Kadam, U.T. Clinical comorbidity in patients with osteoarthritis: a case–control study of general practice consulters in England and Walls [Text] / U.T. Kadam, K. Jordan, P.R. Craft // Ann. Rheum. Dis. – 2004. – Vol. 63. – Р. 408–414.
Comorbid Conditions in the AMICA Study Patients: Effects on the Quality of Life and Drug Prescriptions by General Practitioners and Specialists [Text] / R. Caporali, M.A. Cimmino, P Sarzi–Puttini [et al.] // Sem. Arthr. and Rheum. – 2005. – Vol. 35, Is. 1. Suppl.1 . – Р. 31–37.
Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis / L.H. Kuller, R.H. Mackey, B.T. Walitt [et al.] // Arthritis Rheumatol. – 2014. – Vol. 66 (3). – Р. 497-507.
Grading of Recommendations Assessment, Development and Evaluation[Text] / O. Bruyere, N. Burlet, P. Delmas [et al.] // Evaluation of Symptomatic Slow–Acting Drugs in Osteoarthritis Using the GRADE System. BMC Musculoskelet Disord. – 2008.
Badokin, V.V. Knee osteoarthrosis: Clinical presentation, diagnosis, treatment [Text] / V.V. Badokin // Modern Rheumatology. – 2013. – Vol. (3). – Р. 70-75.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying
antirheumatic drugs: 2013 update / J.S. Smolen, R. Landewé, F.C. Breedveld [et al.] // Ann. Rheum. Dis. – 2014. – Vol. 73 (3). – Р. 492-509.
Oral chondroprotection with nutraceuticals made of chondroitin sulphate plus glucosamine sulphate in osteoarthritis [Text] / C. Bottegoni, R.A. Muzzarelli, F. Giovannini [et al.] // J. Carbohydr. Polym. – 2014. – Vol. 30. – Р. 126-138.
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis [Text] / D.O. Clegg, D.J. Reda, C.L. Harris [et al.] // N. Engl. J. Med. – 2006. – Vol. 354. – Р. 795–808.
Hochberg, M.C. Structure–modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta–analysis of randomized placebo– controlled trials of 2–year duration [Text] / M.C. Hochberg // Osteoarthritis Cartilage. – 2010. – Vol. 18. (Suppl 1.). – Р. 28–31.
OARSI recommendations for the Management of hip and knee osteoarthritis Part III: changes in evidence following systematic cumulative update of research published through January 2009 [Text] / W. Zhang, G. Nuki, R.W. Moskowitz [et al.] // Osteoarthr. Cartilage. – 2010. – Vol. 18 (4). – Р. 476-499.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2020 Annals of Mechnikov's Institute
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
